Analyst Opinion on Perrigo Co. and Auxilium Pharmaceuticals

Analyst Opinion on Perrigo Co. and Auxilium Pharmaceuticals Inc. -
Drug Related Product Companies Remain Healthy 
LONDON -- (Marketwire) -- 11/13/12 --  The drug related products
industry, which features companies such as Perrigo Co. and Auxilium
Pharmaceuticals Inc., has been making headlines of late. Several
companies have turned in solid quarterly reports, and a plethora of
acquisitions and new product launches has kept the industry in the
limelight. With president Obama remaining in the White House,
companies in the industry could also stand to benefit from his
Affordable Health Care Act, as more Americans will be insured. 
www.WallStreetActive.com is unswerving when it comes teaching the new
and pro traders on how to take the helm in a market environment that
has been seeing waves upon waves of changes and reap the rewards of
participating in various sectors. We invite serious traders to join
our financial community so that they can benefit from our free
analytical coverage on Perrigo Co. (NASDAQ: PRGO) and Auxilium
Pharmaceuticals Inc. (NASDAQ: AUXL) by signing up at 
http://www.wallstreetactive.com/register.php  
With earnings season in full swing, investors have been able to take
a closer look at individual companies in the industry. Some, like
Perrigo, have reported increased sales from their over-the-counter
products, while others have seen their prescription segments grow.
Analyst opinion on Perrigo Co. accessible for free at 
http://www.wallstreetactive.com/PRGO13November12.pdf 
The industry is facing a number of headwinds though. Research and
development costs remain high, and offer no guarantee on investment.
Yet some, like Auxilium Pharmaceuticals, recently posted a decline of
25.4% in its R&D expenses as a result of inferior spending on its
Peyronie's studies. See what our analysts have to say on Auxilium
Pharmaceuticals Inc. Follow the Link below 
http://www.wallstreetactive.com/AUXL13November12.pdf 
Competition in the industry is fierce, and in some cases has led to
legal battles. That being said, the industry has been turning in
solid numbers, and could continue to do so for the remainder of the
year. 
About Wall Street Active:
 Walls Street Active offers topmost
independent research and investment strategies with the sole purpos
e
of consistently identifying stocks that provide the biggest return on
investment for our subscribers. We provide sharp North American stock
investing opinion with a truly outstanding success rate. Our goal is
for likeminded traders to make a lot of money through our
information. 
Read our Disclaimer 
 http://www.wallstreetactive.com/disclaimer.html 
Contact Person:
Ravi S. Kapur
Telecommunication, Information & Data Manager
info@wallstreetactive.com 
 
 
Press spacebar to pause and continue. Press esc to stop.